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http:WHAT THIS PAPER ADDS
This study suggests that patients with isolated type II endoleak demonstrate equivalent aneurysm-related
mortality and an improved all-cause survival. A conservative approach to the treatment of type II endoleak
appears to be safe.Objective: Type II endoleak is the most common complication after endovascular abdominal aortic aneurysm
repair (EVAR); however, its natural history is unclear. The aim of this study was to examine the incidence and
outcomes of type II endoleak, at a single institution after EVAR.
Methods: A total of 904 consecutive patients who underwent EVAR between September 1995 and July 2013 at a
single centre were entered onto a prospective database. All patients were followed up by duplex ultrasound
(DUSS). Patients who developed type II endoleak were compared for preoperative demographics, mortality, and
sac expansion.
Results: A total of 175(19%) patients developed type II endoleak over a median follow-up of 3.6 years (1.5e5.9
years); 54% of type II endoleaks spontaneously resolved within 6 months (0.25e1.2 years). No difference was
found in preoperative demographics or choice of endograft between the two groups. Survival was signiﬁcantly
higher in the group with type II endoleak (94.1% vs. 85.6%; p ¼ .01) and this effect was most pronounced in
those with late type II endoleaks (97.7% vs. 85.6% p ¼ .004). No difference was seen in aneurysm-related
mortality or rate of type I endoleak between the two groups. Freedom from sac expansion (>5 mm from
preoperative diameter) was signiﬁcantly lower in the group of patients with type II endoleak (82.5% vs. 93.2%,
p ¼ .0001); however, at a threshold of >10 mm from preoperative diameter no difference was seen.
Conclusions: Patients with isolated type II endoleak demonstrate equivalent aneurysm-related mortality and an
improved survival.
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Endoleak may be deﬁned as a continued perfusion of the
aneurysm sac despite endograft deployment. Type II endo-
leak is themost common type of endoleak, themost frequent
complication of endovascular abdominal aortic aneurysm
repair (EVAR) occurring in approximately 10% of patients1
and may be deﬁned as the backﬂow of blood from aortic
collateral arteries into the aneurysm sac. Despite this, the
natural history of type II endoleak is currently unclear, with
several retrospective studies suggesting it to be a benign
complication2 while others have associated type II endoleakTo access continuing medical education questions on this paper,
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sion and rupture.
Aortic aneurysm rupture after EVAR secondary to an
isolated type II endoleak is rare5 and the impact of sac
expansion on risk of rupture in patients with an isolated type
II endoleak is unknown. The decision to intervene is often
down to surgeon preference and although vascular centres
that do not routinely attempt to abolish the type II endoleak
(with or without sac expansion) have reported good out-
comes,2 an optimal strategy for treatment is currently
lacking.6 The aim of this study was to examine the incidence
and outcomes of type II endoleak, at a single institution that
conservatively manages patients with type II endoleak.METHODS
Within this study, 904 consecutive patients who underwent
EVAR for AAA between September 1995 and July 2013 at a
single centrewere entered ontoa prospectivedatabase. EVARs
were performed by a dedicated vascular team with choice of
392 D.A. Sidloff et al.endograft being dependent on aortoiliac morphology and
operator preferences. Collected data included preoperative
patient demographics, for example the presence of comor-
bidities (smoking, diabetes, chronic renal failure, ischaemic
heart disease, hypertension, and cerebrovascular disease),
preoperative aneurysm diameter, and intraoperative details.
Following EVAR, patients were followed up at regular
outpatient appointments with clinical examination and
duplex ultrasound scan (DUSS) at 1, 3, and 6 months
postoperatively, and at 6-monthly intervals thereafter. At
the time of DUSS, data were recorded on sac size, including
the presence or absence of endoleak. Computed tomogra-
phy (CT) scans were performed as necessary to conﬁrm or
clarify complications detected by DUSS. All outcomes
including the presence of endoleak, stent migration, stent
kinking, conversion to open surgical repair, rupture, and
death were recorded prospectively on a research database.
Those patients in whom DUSS was not possible due to large
body habitus were followed up with yearly CT scans with
data as above recorded.
Currently DUSSs are performed by a trained vascular
technician using a GE Logiq E9 scanner (Fairﬁeld, CA, USA)
with a C1e5 MHz broadband curved array transducer
(B-mode imaging, colour ﬂow imaging and spectral Doppler
modalities); however, over the study period this centre also
used a Philips Medical Systems HDI 5000 duplex ultrasound
scanner (Bothell WA, USA) with a C5e2 MHz broadband
curved array transducer (B-mode imaging, colour ﬂow im-
aging, and spectral Doppler modalities). B-mode imaging of
the aneurysm sac was performed in transverse and longi-
tudinal planes to identify the graft and to examine the sac
contents. The maximum sac diameter (outer wall to outer
wall) was measured in both anteroposterior and lateral
planes (side-to-side diameter from the coronal position)
and any changes in sac size were determined. Outer wall to
outer wall diameter measurements have recently been
demonstrated to have a high repeatability and reproduc-
ibility.7 Colour ﬂow imaging was the principal method used
to examine the sac for evidence of endoleak. The colour
ﬂow scanner controls were also optimized to detect low-
velocity ﬂow from very small endoleaks. Spectral Doppler
recordings were taken from any endoleak to examine ﬂow
characteristics (pendulum ﬂow suggesting a blind-ending
endoleak, or directional ﬂow that might suggest both
inﬂow and outﬂow). Type II endoleak was deﬁned as blood
ﬂow outside the stent graft but within the aneurysm sac
caused by retrograde ﬁlling from aortic side branches.
Patients with inﬂammatory or infective aneurysms were
excluded from this study. The primary analysis performed
aimed to compare those with type II endoleak against a
group with no post-EVAR complications by excluding all
patients who died within 30 days of EVAR and those who
developed other complications of EVAR, for example
endoleak (other than type II endoleak), graft migration, and
graft kinking. A subgroup analysis aimed to compare out-
comes in those with type II endoleak against those without
type II endoleak. The no type II endoleak group included
patients who had died within 30 days of EVAR and thosewho had developed other complications of EVAR, for
example endoleak (other than type II endoleak), graft
migration, and graft kinking. Dangerous/life-threatening
complications of EVAR were recognized at follow-up and
treated urgently to prevent death, and all type I endoleaks
detected in clinic were admitted with a view to inpatient
treatment. Any type I endoleak detected on completion
angiogram were treated within the ﬁrst operation. The
primary outcome measures were all-cause mortality,
aneurysm-related mortality, and freedom from aneurysm
growth. Separate analysis were performed in patients with
more than 5 mm of sac expansion (compared to original sac
size) and those with more than 10 mm of sac expansion
(compared to original sac size). Secondary outcomes
included spontaneous resolution of the endoleak, deﬁned
as no visible type II endoleak on two consecutive DUSS with
no intervention having been performed.Statistical analysis
Patients were analysed separately according to the pres-
ence or absence of a type II endoleak. Those with type II
endoleak were further classiﬁed according to the nature of
type II endoleak including early (ﬁrst imaged on initial post
EVAR DUSS), late (ﬁrst imaged more than 12 months after
EVAR), and persistent (present for more than 6 months).
Continuous variables were expressed as mean and standard
deviation (SD) or median and interquartile range (IQR)
depending on the variance, and were analysed by the Fisher
exact test or the ManneWhitney U test where appropriate.
KaplaneMeier analysis was used to estimate all-cause
mortality survival rates and freedom from aneurysm sac
growth rates with log rank analysis used to test the equality
of survival distributions between different factors.
Censoring occurred on the last date that a patient was
known to be alive or had attended an outpatient appoint-
ment if lost to follow-up. Cox proportional hazards regres-
sion was used to test for independent associations with risk
of type II endoleak and sac expansion with results expressed
as odds ratios (OR) and conﬁdence intervals (CI). Stepwise
selection of the following covariates was performed: age,
sac diameter, ischaemic heart disease, hypertension, dia-
betes, cerebral vascular disease, hyperlipidaemia, chronic
renal failure, current smoking, and gender. All statistical
analyses were performed using SPSS v.20 (IBM Corp,
Armonk, NY, USA) and assumed to be signiﬁcant if p < .05.
RESULTS
During the study period, 904 consecutive patients under-
went EVAR. From these 904 patients, follow-up data were
available on 773 patients who were included into the
analysis (data completeness 86%) from which 175 (19%)
patients developed type II endoleak (Table 1). No differ-
ences could be seen in the baseline characteristics of those
patients lost to follow-up compared to those included
within the analysis (Supplemental Table 1). Median follow-
up was 4.1 years (1.8e6.2 years) in the no complication
group and 3.6 years (1.5e5.9 years) in the type II endoleak
Table 1. Baseline characteristics of patients with and without type II endoleak.
Type II endoleak (n ¼ 175) No type II endoleak (n ¼ 598) p
Follow-up (yrs)a 3.6 (1.5e5.9) 4.1 (1.8e6.2)
Age (yrs) 74.9  6.6 74.0  8.4 0.1
Spontaneous resolution 95 (54.2) e
Time to resolution (yrs)a 0.63 (0.25e1.2) e
Male 157 (89.7) 553 (92.5) 0.3
Aneurysm diameter (mm) 64  11 63  10 0.5
Hypertension 70 (40) 254 (42.5) 0.6
Ischaemic heart disease 55 (31.4) 183 (30.6) 0.8
Hyperlipidaemia 63 (36) 210 (35.1) 0.8
Diabetes 18 (10.3) 63 (10.5) 1.0
Chronic renal failure 6 (3.4) 33 (5.5) 0.3
Cerebrovascular disease 11 (6.3) 41 (6.9) 0.9
Smoking 95 (54.3) 334 (55.9) 0.7
Note. Continuous data are shown as the mean  standard deviation and categoric data are shown as number (%).
a Median and interquartile range.
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tive demographics between the two groups. Within the
group who developed type II endoleaks (Table 2), 59
developed early type II endoleak, 53 developed late type II
endoleak, and 81 developed persistent type II endoleak.
Within the persistent type II endoleak group were 31 late
type II endoleaks and 26 early type II endoleaks. Sponta-
neous resolution of the endoleak occurred in 95 (54.2%) of
all type II endoleaks after a median of 0.63 years (0.25e1.2
years). Comparing the rate of spontaneous resolution be-
tween different types of endoleak, there appears to be a
higher rate of spontaneous resolution within the early
endoleak group (78%) than in the late and persistent type II
endoleak groups (53% vs. 53%). Furthermore, the early
endoleak group appear to spontaneously resolve earlier
(0.26 years, 0.13e0.94 years) than the late (1.04 years,
0.6e2.2 years) and persistent (1.3 years, 0.9e2.2 years)
groups.
Type II endoleak rates were comparable regardless of the
type of endograft used (Table 3). Cox regression analysis
adjusted for covariates (age, sac diameter, ischaemic heart
disease, hypertension, diabetes, cerebral vascular disease,
hyperlipidaemia, chronic renal failure, current smoking, andTable 2. Baseline characteristics of patients with different classiﬁcatio
Early type II endoleak (n ¼ 59) Late t
Median follow-up (yrs)a 3.7 (1.7e5.6) 5.6 (3
Age (yrs) 75.3  7.4 74.8
Male 52 (88.1) 43 (8
Aneurysm diameter (mm) 64  11 66 
Spontaneous resolution 46 (78) 25 (4
Time to resolution (yrs)a 0.26 (0.13e0.94) 1.04
Hypertension 23 (39) 15 (2
Ischaemic heart disease 15 (25) 9 (17
Hyperlipidaemia 13 (22) 13 (2
Diabetes 5 (8.5) 4 (7.5
Chronic renal failure 1 (1.7) 0 (0)
Cerebrovascular disease 1 (1.7) 3 (5.6
Smoking 29 (49.1) 20 (3
Note. Continuous data are shown as the mean and standard deviation
a Median and interquartile range.gender) failed to identify any signiﬁcant associations with
the risk of developing type II endoleak.The association of type II endoleak with type I endoleak
Within the study period, 27 patients developed type 1
endoleak, six of whom had a type II endoleak. Three of
these patients had a persistent and late type II endoleak
from which two developed 10 mm of sac expansion. One
patient had a persistent type II endoleak and no sac
expansion, and two patients had type II endoleak with no
sac size changes. Thirty-one patients had both a persistent
and late type II endoleak from which only three developed a
type I endoleak. These data demonstrate no association
between type II endoleak and the development of a type I
endoleak (p ¼ 1.0).All-cause and aneurysm-related survival
Analysis of patients with type II endoleak versus a post
EVAR, no complication group demonstrated an improved
all-cause survival in patients with type II endoleak
compared to those with no complication; 94.1% versus
85.6% at 3 years and 80% versus 71.4% at 5 years (p ¼ .04),ns of type II endoleak.
ype II endoleak (n ¼ 53) Persistent type II endoleak (n ¼ 81)
.6e8.6) 5.1 (2.5e7.3)
 6.7 74.4  6.6
1.1) 71 (87.7)
12 66  1.2
7.2) 43 (53)
(0.6e2.2) 1.3 (0.9e2.2)
8) 33 (40.7)
) 19 (23.4)
4.5) 25 (30.9)
) 8 (9.9)
1 (1.2)
) 9 (11.1)
7.7) 44 (54.3)
and categoric data are shown as number (%).
Table 3. Type II endoleak distribution by device models.
Device Type II endoleak
(n ¼ 175)
No type II
endoleak
(n ¼ 598)
p
No. (%) No. (%)
Cook Zenith 91 (52) 304 (51) 0.8
Cook Trifab 15 (8.6) 52 (8.7) 1.0
Medtronic endurant 18 (10) 54 (9) 0.6
Talent 18 (10) 57 (9.5) 0.6
Anaconda 2 (1) 14 (2.3) 0.5
Gore excluder 24 (14) 79 (13.2) 0.9
Edwards lifepath 2 (1) 2 (0.3) 0.2
Cook uni iliac e 9 (>1) e
Local device e 5 (>1) e
394 D.A. Sidloff et al.a ﬁnding which persists out to 9 years; 47.7% versus 41.9%
(Fig. 1). This remained signiﬁcant when including patients
with known complications into the non-type II endoleak
group: 94.1% versus 85.3% at 3 years, which perseveres to 9
years, 47.7% versus 40.4%; p ¼ .01.
Analysing all-cause mortality within the different classi-
ﬁcations of type II endoleaks, those with late endoleaks
appear to have a signiﬁcant survival advantage compared to
those with no complication (Fig. 2(A)): 97.7% versus 85.6%
at 3 years which persists to 9 years; 56% versus 41.9%,
p ¼ .008. This again remained signiﬁcant when includingFigure 1. KaplaneMeier analysis comparing cumulative all cause s
complication. Log rank (Mantel Cox), p ¼ .04.patients with known complications into the analysis: 97.7%
versus 86.3% at 3 years and 56% versus 41.4% at 9 years
(p ¼ .004) over those without type II endoleaks. Analysing
survival in patients with persistent and early type II endo-
leak versus those with no complications demonstrated no
difference in all-cause mortality (Fig. 2(B and C)).
No signiﬁcant difference was demonstrated between
aneurysm-related mortality in the group of patients with
type II endoleak compared to the group without compli-
cation: 98.1% versus 100% at 5 years and 96.8% versus 98.3
at 7 years (p¼ .44). Eleven aneurysm ruptures occurred at a
median of 41 months after discharge (IQR 9.5e52.5
months) from which two occurred in the perioperative
period and nine occurred after discharge from hospital. The
principle complication associated with rupture was a type 1
endoleak (n ¼ 7). One patient was reported to have a type
III endoleak and consequently ruptured prior to a bridging
stent being placed while another patient had a stent strut
fracture. One patient who underwent elective EVAR aged
71 for a 90 mm AAA developed a persistent type II endoleak
18 months after EVAR and sac expansion (more than 10 mm
from original sac size). The type II endoleak was treated
conservatively and the patient was admitted with a prox-
imal type 1 endoleak 56 months after EVAR, treated with
proximal cuff. At 72 months this patient was admitted withurvival in patients with type II endoleak versus those with no
Figure 2. (A) KaplaneMeier analysis comparing cumulative all cause survival in patients with a late type II endoleak (visualized after 1 year
of follow-up) versus those with no complication. Log rank (Mantel Cox), p ¼ .008. (B) KaplaneMeier analysis comparing cumulative all
cause survival in patients with a persistent type II endoleak (more than 6 months) versus those with no complication. Log Rank (Mantel
Cox), p ¼ .8. (C) KaplaneMeier analysis comparing cumulative all cause survival in patients with an early type II endoleak (visualized on
ﬁrst follow-up) versus those with no complication. Log rank (Mantel Cox), p ¼ .06.
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II endoleak presented with a ruptured AAA.
Sac expansion
Freedom from sac expansion (an increase of 5 mm from
preoperative sac size) was demonstrated to be signiﬁcantly
lower in the groupof patientswith type II endoleak than in the
group without complication (Fig. 3) at 3 years (82.5%
vs. 93.2%), a ﬁnding that canbe demonstrated throughout theduration of follow-up (p ¼ .0001). Freedom from sac expan-
sion of more than 10 mm from preoperative sac size was
however comparable between the two groups (p ¼ .1). Cox
regression analysis adjusted for covariates (age, sac diameter,
ischaemic heart disease, hypertension, diabetes, cerebral
vascular disease, hyperlipidaemia, chronic renal failure, cur-
rent smoking, and gender) conﬁrmed a strong independent
association between the presence of type II endoleak and the
likelihood of sac expansion (more than 5 mm) after EVAR (OR
Figure 3. KaplaneMeier analysis comparing freedom from sac expansion (more than 5 mm) in patients with type II endoleak (visualized
after 1 year of follow-up) versus those with no complication. Log rank (Mantel Cox), p ¼ .0001.
396 D.A. Sidloff et al.3.3, 95% CI 1.87e4.91; p ¼ .0001) but failed to demonstrate
this with sac expansion of more than 10 mm (Fig. 4, p ¼ .1).Reintervention after EVAR
Interventions to abolish a type II endoleak were not
routinely performed after any speciﬁc time period or at any
speciﬁc sac diameter change; thus, any decision to inter-
vene was down to surgeon/patient preference. A total of
nine interventions have been performed to embolize a type
II endoleak. (One direct sac puncture and eight transarterial
interventions.) Seven of these interventions were in pa-
tients who had more than 10 mm of sac expansion and
three out of the nine interventions were clinically successful
(deﬁned as no type II endoleak present on repeat DUSS).
Three patients underwent repeat reintervention: one IMA
clipping, one transarterial coil, and one conversion to open
surgical repair, all of which were successful. The patient who
underwent conversion to open repair had a persistent type
II endoleak, failed transarterial intervention and sac
expansion from 51 mm to 77 mm. No post-intervention
major complications occurred.
DISCUSSION
This study demonstrates that the conservative management
of type II endoleak is not associated with an increase in theriskof aneurysm-relatedmortality, all-causemortality, 10mm
of sac expansion, or type I endoleak. These data therefore
suggest that a conservative approach to the treatment of
type II endoleak is safe. Only three out of the nine in-
terventions performed to abolish a type II endoleak were
successful, which is in line with previous data suggesting a
high risk of treatment failure.5 Although no complications
were noted after intervention in this study, Haulon et al.8
reported a post-transarterial intervention, mesenteric
thrombosis, whereas Uthoff and colleagues9 reported a pul-
monary embolism secondary to leaked embolent and an
endograft perforation. The risk of an aggressive approach
(treating all type II endoleaks or those with 5 mm of sac
expansion) may therefore outweigh any beneﬁt.
In keeping with previous ﬁndings,10 type II endoleak was
not associated with an increase in aneurysm related mor-
tality; however, it was associated with an increased survival:
94.1% versus 85.3% p ¼ .01. This ﬁnding was most pro-
nounced in those with late-onset type II endoleaks (those
that developed after 1 year of follow-up): 97.7% versus
86%, p ¼ .004. Although these data are not the ﬁrst to note
this unintuitive ﬁnding,10 no clear explanation currently
exists. Previous studies3,4,11 have demonstrated an associ-
ation between persistent type II endoleaks and adverse
outcomes; however, these data demonstrated no increase
in aneurysm or all-cause mortality in this group of patients.
Figure 4. KaplaneMeier analysis comparing freedom from sac expansion (more than 10 mm) in patients with type II endoleak (visualized
after 1 year of follow-up) versus those with no complication. Log rank (Mantel Cox), p ¼ .1.
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in those with type II endoleak could be differences in patient
demographics. Although no differences were seen between
patient comorbidities in this study, Van Marrewijk et al.11
found current smoking and a decreased ankleebrachial in-
dex (0.87 or less) to reduce the risk of type II endoleak. El
Batti3 and colleagues similarly demonstrated that the risk of
type II endoleak was reduced in active smokers (OR 0.16, CI
95% 0.04e0.71, p ¼ .01) and patients with coronary artery
disease (OR 0.65, CI 95% 0.45e0.92, p ¼ .01). It is plausible
that those patients with type II endoleak have less profound
atherosclerosis both peripherally and centrally; however,
studies to demonstrate a reduced cardiovascular risk in this
group of patients would be required to investigate this.
This study conﬁrms an association between type II
endoleak and sac expansion of 5 mm, which is in keeping
with previous studies3,4; however, although growth of more
than 5 mm has been shown to represent an actual change
in aneurysm size rather than a measurement error,12
intervention at this point is not evidence based. Current
guidelines from the European Society of Vascular Surgery13
are that a conservative approach is appropriate for type II
endoleak without sac expansion. Intervention is recom-
mended in the presence of an increased sac diameter of
10 mm or more, with conversion to open surgery ifendovascular treatment fails (level 2b).13 This study failed
to show any association between type II endoleak and sac
expansion of more than 10 mm from preoperative sac size.
Within this study, 54.2% of all type II endoleaks sponta-
neously resolved within a median of 7 months. The number
of type II endoleaks that spontaneously resolve is variable
between studies; for example, one study2 demonstrated that
48% will resolve within 4 years while another4 suggested
that 80% would resolve within 6 months. Taken together
these studies suggest that given time, type II endoleak have
a reasonable chance of spontaneously resolving, a view
which has been conﬁrmed by a systematic review which
demonstrated that a third of all isolated type II endoleaks
spontaneously resolve up to 4 years after EVAR.5
Choice of imaging is likely to affect the reported incidence
of type II endoleak.14,15 CT has been reported in some studies
to achieve the highest sensitivity and speciﬁcity for the
detection of endoleak15; however, in an effort to reduce the
cumulative risk of radiation exposure associated with lifelong
follow-up, many vascular centres have evolved to DUSS
surveillance with CT only used to conﬁrm suspected com-
plications. Although DUSS surveillance may be a limitation of
this study, Schmieder and colleagues16 recently demon-
strated that colour duplex imaging has a higher sensitivity in
detecting endoleaks requiring intervention (90% vs. 58%)
398 D.A. Sidloff et al.and has a better diagnostic accuracy in identifying the type of
endoleak than CT, which can be improved further by utilizing
contrast-enhanced ultrasound.17 Contrast-enhanced ultra-
sound was not utilized during any parts of this study. Gray
et al.18 demonstrated that colour duplex imaging had a
sensitivity of 100% (speciﬁcity of 85%) and could replace CT
as the ﬁrst-line surveillance tool following EVAR as it was
associated with a reduction in the cost of surveillance
without any loss of imaging accuracy. A further limitation of
DUSS in general is that it is operator dependent and that its
sensitivity can be reduced in patients with a raised BMI.19
Furthermore, it is possible that some type II endoleaks are
misdiagnosed type I or type III endoleak.
Some studies have suggested that diameter changes after
EVAR correlate poorly with volumetric changes, which may
bemore informative. Future follow-upmay therefore include
three-dimensional ultrasound imaging. This study is limited
by its retrospective nature; however, all outcomes including
the presence of endoleak, conversion to open surgical repair,
rupture, and death were recorded prospectively. Not all
patients attended follow-up (data completeness ¼ 86%);
therefore, outcome data for some patients is unavailable for
analysis; however, this study did include data for 773 pa-
tients. Within this study, the number of EVARs performed
was heavily weighted towards the more recent years. For
example in the year 2000, 23 EVARs were performed while in
2012, 98 EVARs were performed. This reﬂects the increasing
use of EVAR with time and skews the follow-up times ach-
ieved. Although the results of this study appear to highlight
an improved survival in a group of patients with type II
endoleak after EVAR, this association does not suggest that
type II endoleak or growth of the aneurysm after EVAR is
desirable.
A limitation of type II endoleak reporting in general is the
varying deﬁnitions used by authors when referring to early,
late, and persistent type II endoleaks. A classiﬁcation system
for reporting type II endoleaks is necessary to enable
standardization of reporting and comparison of results.
Furthermore, a randomized clinical trial comparing conser-
vative, selective (sac expansion more than 10 mm), and
aggressive management of type II endoleak with adequate
follow-up would be required to establish a gold standard
treatment strategy for these patients. However, the low
outcome event rates in patients with type II endoleaks may
preclude funding for, and recruitment to, such a trial owing
to the large sample sizes required.20 Data such as those
reported in this study should be gathered on an interna-
tional database to enable robust analysis of outcomes in
patients with endoleak.
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